profit from every $100 of sales.
$0$100
Abivax
$91.44+1.60% today
-17.2% in 1 year
1-year low $72.501-year high $145.31
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Abivax sold, what it kept, and what it did with the cash.
Sales went from €0 in 2022 to €0 in 2025, with -€336 million of profit last year.
SalesProfit
Abivax vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Abivax | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Abivax's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| -51 | – | – | – | |
| -51 | -127 | -173 | -246 | |
| -53 | -133 | -163 | -301 | |
| -61 | -148 | -176 | -336 | |
| -3.18 | -3.43 | -2.78 | -4.83 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 76 | 327 | 205 | 584 |
| Cash | 27 | 252 | 144 | 517 |
| Total debt | 39 | 58 | 97 | 2 |
| Total liabilities | 68 | 131 | 165 | 129 |
| 7 | 196 | 41 | 455 | |
| 19 | 43 | 63 | 70 | |
| -91.7% | -41.6% | -93.8% | -52.2% | |
| -844.9% | -75.4% | -434.3% | -73.8% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -54 | -97 | -154 | -161 | |
| 0 | 0 | 1 | 0 | |
| -54 | -97 | -155 | -161 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| -1 | 8 | 20 | 35 |
Valuation
- –
- –
- –
- 15.8×
- –
- –
- –
- -2.5%
- -5.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -48.0%
- -88.1%
- -165.2%
- -57.5%
- -48.1%
- –
Growth
- –
- –
- −0.7%
- –
- +45.6%
Financial health
- 1.9×
- 0.07
- 5.5%
- -8.8×
- 8.75
- 8.75
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 958
Bottom 21%of 888
Bottom 26%of 987
What analysts expect
- Average price target
- $146.13
- Range
- $110.00 – $176.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 23, 2026 | -1.22 | -1.07 | −13.8% |
| Sep 8, 2025 | -0.86 | -0.90 | +4.4% |
| Mar 24, 2025 | -1.55 | -0.68 | −128.0% |
| Nov 7, 2024 | -0.70 | -1.28 | +45.5% |
| Apr 2, 2024 | -1.94 | -0.91 | −112.7% |
| Jun 30, 2023 | -1.58 | – | – |
| Dec 31, 2022 | -1.95 | -1.93 | −0.8% |
| Jun 30, 2022 | -1.84 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
40No pass
Philip Fisher
27No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
17No pass
Terry Smith
11No pass
Questions about Abivax
Is Abivax a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Abivax AI analysis
What does Abivax do?
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. It is in Biotechnology, based in Paris, France, with 80 employees.
Does Abivax pay a dividend?
No. Abivax does not pay a dividend at the moment.
Is Abivax stock halal?
Yes. Abivax passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Abivax stock done over the past year?
Down 17.2% over the past twelve months, to $91.44. It traded between $72.50 and $145.31 and is 37.1% below its high.
Who are Abivax's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Abivax's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.